01.12.2016

1

Biomarker strategy for Personalized

Healthcare at Roche

E mi l i a And e r sso n o n b e h a l f o f t h e

I R I S t e a m– No v 2 0 1 6

6th Munich Biomarker Conference Nov 29th – 30th, 2016 Ramada Hotel & Conference Center, Munich, Germany

Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany

Personalized Healthcare at Roche

Ou r l o ng st a nd i ng v i si o n

Roche’s vision is to unlock the full potential of

personalized healthcare for patients through the

development of breakthrough medicines and

leading diagnostics.

2

01.12.2016

2

Roche’s Evolving PHC Strategy

I nd i v i d u a l i se d

t r e a t me nt s c o mi ng wi t h i n

r e a c h

3

Individualised Treatments

Targeted Medicines

Blockbuster Drugs

Patient scope

Individuals

Specific groups

Broad

disease

segments Better understanding

of disease heterogeneity

Molecular information:

Digitisation of healthcare data

Until 1990s 2000/2010s 020+

Roche‘s evolving PHC Strategy R e a d y t o t a k e

t r a nsf o r ma t i o na l st e p Big Data are shifting boundaries of what is and

will be possible in medical research and patient care

This is the next stage in

Personalized Healthcare at Roche

Science and technology will work together,

combining insights from multiple

healthcare data sources with sophisticated analytics

This will transform R&D,

so it is more effective and efficient

And allow for better, evidence-based

decisions and personalized patient care

01.12.2016

3

Access meaningful data Create insights

Advanced analytics

of integrated data

Realise value from insights

Drive more effective

and efficient R&D

Improve access &

personalised

patient care

Roche’s evolving PHC Strategy

Real World

Data

Clinical Trial

Data

5

Da t a a na l y t i c s t o

i mp r o v e R & D a nd p a t i e n t

c a r e

Defining analytics and workflows that extend tissue analysis to include clinical

imaging, molecular information and clinical data for translational research

Integrated platform for tumor analysis

and study management

Clinical

Imaging

Pathology

Data

Molecular

Data

Clinical

Data

Analytics & Results

Data & Project

Management

Lab Workflow/

Sample handling

CRO Dataflow management

Research Data Hub

IRIS - database designed to capture the

patient context and tumor biological

landscape

01.12.2016

4

Keeping data in its context Usi ng sp a t i a l l y d i st r i b u t e d

i n f o r ma t i o n f o r

e p i d e mi o l o g y

Keeping data in its context T e c h no l o g i e s a v a i l a b l e

f r o m g e o g r a p h i c

i n f o r ma t i o n sy st e ms

01.12.2016

5

LIMS

Biomarker

database

Genomic

databas

e

Clinical

databas

e

The IRIS database is designed to capture the

patient context and tumor biological

landscape

9

Generate high throughput,

high quality, whole slide

standardized biopsy images

from automated assays

(incl. multiplexing)

Collect and organize

complex data from images

to enable distribution and

correlative analysis

Analyse and visualize

contextual data for

understanding and

interpretation

Tumors are complex, heterogeneous

structures

De si g ne d t o a v o i d o u r

d e f e nse me c h a n i sms

Origin

Structure Distribution

Molecular information

01.12.2016

6

The IRIS database is designed to capture the

patient context and tumor biological

landscape

Prevalence tool designed to retrospectively dive deeper into the data from all samples in the database

T-cell density and spatial distribution

measurements capture the contexture of immune

cells and proximity to tumor and stroma

Ki67 tumor cell

Close

distance

Large

distance

CD8 T-cell

Radius

Localisation and distances of

detected objects, e.g. T-cells,

tumor cells

Dynamic interplay of any cell

population and/or subpopulation

with a given reference point (e.g.

immune cell, tumor cell, stromal

cell, vessel…)

01.12.2016

7

Immune cell infiltration in tumor nest

-Important sign of tumor cell

recognition/eradication?

CRC patients from

internal pilot study

4 % of tumor cells in close

contact to T-cells

21 % tumor cells in close

contact to T-cells

MSI MSS

Ki67 tumor cell

CD8 T-cell

On the look for distinguishing features....

g e ne r a t i ng i nsi g h t s

MSS MSI

PD-L1: IC score 0-1

PD-L1: IC score 2-3

PD

1 d

ensity

PD-L1

PD-1

01.12.2016

8

Realizing value

More effective and

efficient research allow

better patient outcomes.

PHC Pillars

Generating insights

Transforming medicine

with insights from

data and analytics.

Access meaningful data

Making sense of the

complexity of today’s

vast research and

healthcare data.

15

IRIS

• pRED Oncology

• pRED informatics

• pRED Pharma Sciences

• Dx Information Solutions (DIS)

• RTD Digital Pathology

• CPS Rare reagents

01.12.2016

9

Do i ng no w wh a t

p a t i e n t s ne e d

ne x t